Clinical Trial Update: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

STAR0602, a bifunctional TCR-targeting antibody-fusion, is being studied in a Phase 1/2 trial for advanced solid tumors and related female genital/urogenital ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Genital Neoplasms
• Human Papillomavirus Infection
• Lung Cancer
• Solid Tumors
• Urogenital Cancer
• Vulvar Cancer

Drugs mentioned

• STAR0602

Snippet

Sponsor: Marengo Therapeutics, Inc. | Conditions: Advanced Solid Tumors, Genital Neoplasm, Female | Phase 1, Phase 2 | Status: RECRUITING